Anthracycline-induced cardiotoxicity: report of fatal cases
Main Article Content
Keywords
Chemotherapy, Cardiotoxicity, Heart failure, Anthracycline
Abstract
Background: Anthracyclines are effective drugs in pediatrics cancer treatment. However, anthracycline-induced cardiotoxicity (AIC) is a serious adverse drug reaction that affects the survival in patients treated for childhood cancer.
Clinical cases: Case 1: Nine-year-old girl with stage IV Hodgkin lymphoma with 12 epirubicin doses and a cumulative dose of 576 mg/m2. After last chemotherapy dose, the patient was admitted with systemic inflammatory response, asthenia and adinamia. Echocardiography: LVEF of 22 %, SF 11% and moderate mitral regurgitation. Patient died 2 days after diagnosed with dilated cardiomyopathy secondary to anthracyclines. Case 2: Fifteen-year-old girl with stage IV Burkitt lymphoma with two epirubicin doses and a cumulative dose of 90 mg/m2. After the last cycle, the patient developed several infectious foci. Echocardiography: LVEF of 49 %, SF 20% and dilated left ventricle with septal flattening. Patient died 13 days after diagnosis of dilated cardiomyopathy by anthracyclines.
Conclusion: AIC is a problem in pediatric patients receiving anthracyclines, monitoring is essential to detect the onset of cardiac damage to provide an intervention to prevent heart failure progress.
References
Muggia FM, Green MD. New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol. 1991;11(1):43-64.
Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8(8):1039-58.
Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525-33.
Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of oncology: European Society for Medical Oncology / ESMO. 2002;13(6):819-29.
Lipshultz SE, Diamond MB, Franco VI, Aggarwal S, Leger K, Santos MV, et al. Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers. Paediatric drugs. 2014 Oct;16(5):373-89. doi: 10.1007/s40272-014-0085-1.
Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900-9.
Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol. 2013;10(12):697-710.
Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27(1):53-68.
Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy A, et al. Role of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer. Journal of clinical oncology. 2010;28(8):1308-15.
Toro-Salazar OH, Gillan E, O’Loughlin MT, Burke GS, Ferranti J, Stainsby J, et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging. 2013;6(6):873-80.
Shaikh AS, Saleem AF, Mohsin SS, Alam MM, Ahmed MA. Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. BMJ Open. 2013;3(11).
Plana JC. Chemotherapy and the heart. Revista Espanola de Cardiología. 2011;64(5):409-15.
Van Laar M, Feltbower RG, Gale CP, Bowen DT, Oliver SE, Glaser A. Cardiovascular sequelae in long-term survivors of young peoples’ cancer: a linked cohort study. Br J Cancer. 2014 Mar 4;110(5):1338-41. doi: 10.1038/bjc.2014.37.
Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Progress in cardiovascular diseases. 2010;53(2):105-13.
Keefe DL. Anthracycline-induced cardiomyopathy. Seminars in oncology. 2001;28(4 Suppl 12):2-7.
Trachtenberg BH, Landy DC, Franco VI, Henkel JM, Pearson EJ, Miller TL, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatric cardiology. 2011;32(3):342-53.
Drafts BC, Twomley KM, D’Agostino R Jr, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6(8):877-85.
Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. European heart journal cardiovascular Imaging. 2013;14(3):228-34.
Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess. 2007;11(27):1-84.
Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. The Cochrane database of systematic reviews. 2011(6):CD003917.